1,048 results match your criteria: "Necrobiosis Lipoidica"
Ulcerative Necrobiosis Lipoidica Involving Atypical Site Over Upper Limb.
Indian J Dermatol
October 2024
Department of Pathology, Command Hospital, Kolkata, West Bengal, India.
Drug Repurposing Using Molecular Network Analysis Identifies Jak as Targetable Driver in Necrobiosis Lipoidica.
JID Innov
November 2024
Integrated Cancer Genomics Division, Translational Genomics Research Institute, Phoenix, Arizona, USA.
Article Synopsis
- Drug repurposing offers a cost-effective strategy for developing therapies for rare diseases, which often face challenges in traditional drug development.
- This study used a new drug identification and repurposing pipeline to discover molecular drivers and potential therapies for psoriasis, leading to the identification of both known and novel disease mechanisms.
- The approach was further applied to necrobiosis lipoidica, revealing important disease drivers and potential treatments, demonstrating a high success rate in matching drugs to identified molecular targets.
Article Synopsis
- Leg ulcers, primarily located below the knee, can stem from various causes with around 80% resulting from chronic venous insufficiency (CVI) or peripheral arterial occlusive disease (PAOD), necessitating diverse medical specialists for treatment.
- The diagnostic approach follows the ABCDE rule, which includes personalized history-taking, bacteriological testing, clinical exams, and additional tests to accurately identify the cause of the ulcer, such as vascular issues or other diseases.
- Effective treatment relies on prompt differential diagnosis, highlighting the need for collaboration among different medical specialties due to the complexity of leg ulcers and the challenges posed by limited high-quality research.
Spatial transcriptomics reveals organized and distinct immune activation in cutaneous granulomatous disorders.
J Allergy Clin Immunol
November 2024
Department of Dermatology, Yale School of Medicine, New Haven, Conn; Department of Pathology, Yale School of Medicine, New Haven, Conn. Electronic address:
Article Synopsis
- Noninfectious cutaneous granulomatous disorders like cutaneous sarcoidosis, granuloma annulare, necrobiosis lipoidica, and necrobiotic xanthogranuloma exhibit distinct immune responses and histological features due to variations in macrophage inflammation.
- The study used spatial transcriptomics to analyze the immune activation patterns in these disorders, revealing that each condition has unique characteristics, such as polarized type 1 responses in cutaneous sarcoidosis and mixed type 1 and type 2 responses in granuloma annulare.
- Findings suggest that different immune activation patterns are associated with specific histological changes, highlighting the complexity and individuality of these inflammatory skin conditions.
Successful recovery of a patient with necrobiosis lipoidica diabeticorum: A case report.
Asian J Surg
December 2024
Department of Plastic Surgery, Affiliated Hospital of Guangdong Medical University, Zhanjiang, Guangdong, China. Electronic address:
New approaches to refractory necrobiosis lipoidica with photodynamic therapy: Case report.
Endocrinol Diabetes Nutr (Engl Ed)
July 2024
Servicio de Dermatología, Hospital General Universitario Santa María del Rosell, Cartagena, Murcia, Spain. Electronic address:
Necrobiosis lipoidica treated using 308nm excimer pulsed light.
Lasers Med Sci
April 2024
North Bristol NHS Trust, Bristol, UK.
Shedding Light on Photodynamic Therapy in the Treatment of Necrobiosis Lipoidica: A Multicenter Real-Life Experience.
Int J Mol Sci
March 2024
Department of Clinical and Experimental Medicine, Section of Dermatology, University of Messina, 98125 Messina, Italy.
Article Synopsis
- Necrobiosis Lipoidica (NL) is a rare skin condition that causes yellowish-brown plaques, mostly affecting middle-aged women on their shins, and is marked by inflammation and collagen degeneration.
- A study conducted on 17 NL patients treated with photodynamic therapy (PDT) from 2013 to 2023 showed varied treatment outcomes, with 29% achieving complete lesion clearance and 59% experiencing partial clearance.
- The findings highlight the need for personalized treatment approaches and standardized protocols to improve the effectiveness of PDT for NL, as current evidence in literature is limited.
A Breakthrough in the Treatment of Necrobiosis Lipoidica? Update on Treatment, Etiopathogenesis, Diagnosis, and Clinical Presentation.
Int J Mol Sci
March 2024
Department of Dermatology and Venereology, Medical University of Bialystok, 15-540 Bialystok, Poland.
Article Synopsis
- Necrobiosis lipoidica (NL) is a rare skin disease often linked to insulin-dependent diabetes, with unclear causes and poor treatment outcomes.
- First-line treatments like topical corticosteroids show varying effectiveness, and other options include tacrolimus, phototherapy, and biologics such as adalimumab.
- Newer therapies like Janus kinase inhibitors and tapinarof are promising, but more research is needed, and early diagnosis may improve treatment responses.
Squamous Cell Carcinoma Arising in Chronic Inflammatory Dermatoses.
Cutis
January 2024
Department of Dermatology, Tulane University, New Orleans, Louisiana. Dr. Kuraitis also is from Roswell Park Cancer Center, Buffalo, New York.
Article Synopsis
- Squamous cell carcinoma (SCC) can develop as a complication of long-term skin inflammatory conditions like labial discoid lupus erythematosus (DLE) and oral lichen planus (OLP).
- Certain skin conditions can lead to SCC in a relatively short time, while others may take decades before a cancer diagnosis.
- Continuous monitoring is critical for conditions like orolabial DLE and chronic wounds, as cancers that develop in these contexts are often aggressive and have higher fatality rates.
Topical Ruxolitinib in the Treatment of Necrobiosis Lipoidica: A Prospective, Open-Label Study.
J Invest Dermatol
September 2024
Department of Dermatology, Mayo Clinic, Scottsdale, Arizona, USA. Electronic address:
Article Synopsis
- Necrobiosis lipoidica (NL) is a rare skin disease with limited treatment options, and this study aimed to evaluate the effectiveness of ruxolitinib, a Jak1/2 inhibitor, for managing NL.
- The phase 2 study involved 12 patients and found that, after 12 weeks of treatment, NL lesions significantly improved, showing a 58.2% decrease in severity.
- Additionally, genetic analysis indicated that ruxolitinib affects specific immune pathways linked to NL, although the study's small size and restricted patient criteria were notable limitations.
The Intersection of Dermatological Dilemmas and Endocrinological Complexities: Understanding Necrobiosis Lipoidica-A Comprehensive Review.
Biomedicines
February 2024
Department of Dermatovenerology, "Carol Davila" University of Medicine and Pharmacy, 020021 Bucharest, Romania.
Article Synopsis
- Necrobiosis lipoidica (NL) is a rare skin disorder primarily affecting women and often linked to diabetes mellitus (DM); this paper reviews its associations with DM, thyroid issues, and metabolic syndrome.
- A systematic search yielded 19 significant studies, revealing that NL frequently coexists with DM (11% to 65.71% of cases), and may appear before DM is diagnosed, indicating a potential connection to insulin needs.
- The study also highlights a notable correlation between NL and thyroid disease, as well as a higher prevalence of metabolic syndrome in NL patients, suggesting that further investigation is needed to understand the relationships between NL and these conditions.
[Compression therapy for inflammatory dermatoses of the legs].
Dtsch Med Wochenschr
February 2024
Klinik für Dermatologie, Venerologie und Allergologie, Ruhr-Universität Bochum, Venenzentrum der Dermatologischen und Gefäßchirurgischen Kliniken, Bochum, Deutschland.
Article Synopsis
- * Conditions with swelling (edema) paired with inflammatory skin issues can safely use compression therapy, which is supported by scientific evidence.
- * The article reviews the scientific basis for using compression therapy in these inflammatory conditions, as well as the limitations and guidelines for its application.
Evaluation of pentoxifylline in the treatment of necrobiosis lipoidica: outcomes in 10 patients.
Int J Dermatol
March 2024
Center for Dermatology Research, Department of Dermatology, Wake Forest School of Medicine, Winston-Salem, NC, USA.
Necrobiosis Lipoidica.
N Engl J Med
January 2024
Peking Union Medical College Hospital, Beijing, China
The realistic positioning of UVA1 phototherapy after 25 years of clinical experience and the availability of new biologics and small molecules: a retrospective clinical study.
Front Med (Lausanne)
November 2023
Department of Dermatology, University of Brescia, Brescia, Italy.
Article Synopsis
- Ultraviolet (UVA) A1 phototherapy has been an effective treatment for various skin conditions since the 1990s, yet its application remains limited to a few dermatology centers even after 30 years.
- A study at a single center reviewed 740 patients treated from 1998 to 2022, assessing treatment outcomes and side effects, revealing significant improvements in several conditions, including morphea and skin sarcoidosis.
- Despite showing good efficacy, the usage of UVA1 phototherapy has decreased over the years due to multiple factors, including possible changes in clinical practices and alternatives available.
Assessment of specificity of dermatopathologic criteria for IgG4-related skin disease.
J Cutan Pathol
February 2024
Department of Dermatology, The University of Iowa Hospitals and Clinics, Iowa City, Iowa, USA.
Article Synopsis
- IgG4-related disease (IgG4-RD) is a recently identified condition affecting multiple systems, and IgG4-related skin disease (IgG4-RSD) can present with various skin symptoms that resemble other conditions.
- This study evaluated the specificity of diagnostic criteria for IgG4-RSD by examining 69 cases of conditions that can mimic IgG4-RSD, looking specifically at histopathologic and immunohistochemical features.
- Results showed that while there were many cases with lymphoplasmacytic infiltrates, few met the specific thresholds for IgG4-RSD, suggesting that the criteria may not be very specific when distinguishing between IgG4-RSD
[Literaturrecherche zur Therapie der Necrobiosis lipoidica in der Kindheit].
J Dtsch Dermatol Ges
October 2023
Universitätsklinik für Dermatologie und Venerologie, Medizinische Universität Graz, Graz, Österreich.
Treatment of recalcitrant disseminated ulcerative necrobiosis lipoidica with ustekinumab.
JAAD Case Rep
November 2023
Department of Dermatology, University of Connecticut School of Medicine, Farmington, Connecticut.
Disseminated perforating necrobiosis lipoidica: A case report and literature review.
Clin Case Rep
October 2023
Department of Dermatology Skin Diseases and Leishmaniasis Research Center, Isfahan University of Medical Sciences Isfahan Iran.
Article Synopsis
- Necrobiosis lipoidica is a rare skin disease primarily found in people with diabetes, characterized by granulomatous lesions.
- The perforating variant of this disease is uncommon, hard to treat, and can be easily identified using dermoscopy.
- A case study is presented involving a 24-year-old woman with type 1 diabetes suffering from disseminated perforating necrobiosis lipoidica.
Treatment options for necrobiosis lipoidica: a systematic review.
Int J Dermatol
December 2023
Department of Dermatology, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.
Article Synopsis
- Necrobiosis lipoidica (NL) is a rare skin condition characterized by collagen degeneration, and existing treatment options have been poorly researched, highlighting the need for better understanding and options.
- This review looks at various treatment approaches for NL, including phototherapy, topical corticosteroids, and newer treatments like JAK inhibitors, based on a literature search from 2016 to 2022 that analyzed 60 articles involving 274 patients.
- The findings suggest that photodynamic therapy showed the most significant improvement in patients, but due to the limited quality of evidence, more rigorous randomized controlled trials are needed for a clearer understanding of treatment effectiveness.
The Role of Lasers in Connective Tissue and Inflammatory Dermatoses: A 10-Year Retrospective Review of 60 Patients in a UK Tertiary Laser Clinic.
Indian Dermatol Online J
August 2023
Department of Dermatology, Laser Division, Salford Royal NHS Foundation Trust Hospital, Stott Lane, Salford, Manchester, United Kingdom.
Article Synopsis
- The study examines the effectiveness of lasers in treating inflammatory dermatoses and connective tissue disorders, noting that previous evidence on this topic is limited.
- A retrospective review of 60 cases treated at a laser clinic from 2010 to 2020 shows that 62% of patients experienced significant improvement, mainly with pulsed dye lasers, while some faced side effects like purpura.
- Despite the study's findings suggesting lasers can help manage challenging skin conditions, it acknowledges limitations due to a lack of objective measures for assessing outcomes.
Molecularly Targeted Therapies for Inflammatory Cutaneous Granulomatous Disorders: A Review of the Evidence and Implications for Understanding Disease Pathogenesis.
JID Innov
September 2023
Department of Dermatology, Yale School of Medicine, New Haven, Connecticut, USA.
Article Synopsis
- Inflammatory cutaneous granulomatous diseases like granuloma annulare, cutaneous sarcoidosis, and necrobiosis lipoidica are characterized by the buildup of activated macrophages in the skin, but treatment options are currently limited.
- The only FDA-approved treatments available are prednisone and repository corticotropin injections, primarily for pulmonary sarcoidosis, while other treatment methods are based on low-quality evidence.
- Recent advancements in understanding the molecular mechanisms behind these diseases may lead to new therapies, and ongoing studies are exploring the use of targeted immunological treatments that could provide valuable insights into disease mechanisms.